Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16666684 | 1.00 | BLM (0.55) | BLMLMNAPTPN1ALDH1A1TP53 | |
| SCHEMBL1410363 | 0.91 | — | — | |
| SCHEMBL1410503 | 0.84 | ALDH1A1 (0.52) | BLMLMNAPTPN1ALDH1A1TP53 | |
| SCHEMBL3577262 | 0.83 | BLM (0.55) | BLMLMNAPTPN1ALDH1A1MEN1 | |
| SCHEMBL1410472 | 0.83 | ALDH1A1 (0.62) | BLMPTPN1ALDH1A1TP53TSHR | |
| SCHEMBL2788144 | 0.83 | BLM (0.55) | BLMLMNAPTPN1ALDH1A1MEN1 | |
| SCHEMBL1410266 | 0.83 | ALDH1A1 (0.56) | BLMPTPN1ALDH1A1TP53TSHR | |
| SCHEMBL19468517 | 0.82 | ALDH1A1 (0.56) | BLMLMNAALDH1A1TP53TSHR | |
| SCHEMBL15476657 | 0.82 | ALDH1A1 (0.56) | BLMLMNAALDH1A1TP53TSHR | |
| SCHEMBL19468469 | 0.82 | ALDH1A1 (0.56) | BLMLMNAALDH1A1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230105725-A1 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | FARNEX INCORPORATED (JP) | 2023-04-06 | — | — | US | disclosed |
| CN-115461084-A | Non-lamellar liquid crystal forming composition with high safety | 法纳克斯株式会社 | 2022-12-09 | — | — | CN | disclosed |
| EP-4098281-A1 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | Farnex Incorporated (JP) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021153635-A1 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | 株式会社ファルネックス | 2021-08-05 | — | — | WO | disclosed |
| US-20160067208-A1 | ADHESION PREVENTING AGENT | FARNEX INCORPORATED (JP) | 2016-03-10 | — | — | US | disclosed |
| EP-2992910-A1 | ADHESION PREVENTING AGENT | Farnex Incorporated (JP) | 2016-03-09 | — | — | EP | disclosed |
| CN-105358190-A | Adhesion preventing agent | FARNEX INC | 2016-02-24 | — | — | CN | disclosed |
| US-7846903-B2 | cubic liquid crystal formulation containing an amphiphilic compound such as 1-O-(5,9,13-trimethyltetradecyl)erythritol and a drug ( excluding a lysosomal enzyme) or cosmetic embedded in the cubic liquid crystal; time release agent | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1813287-A1 | TYPE II CUBIC LIQUID CRYSTAL COMPOSITION | National Institute of Advanced Industrial Science and Technology (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | AQP1, AQP3, SCO2 | BLM 118/4885LMNA 1444/4885PTPN1 4309/4885 |
| US-20160067208-A1 | ADHESION PREVENTING AGENT | EPCAM, ICAM1, VCAM1 | BLM 976/4885LMNA 888/4885PTPN1 1953/4885 |
| US-20230105725-A1 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | LIPA, PHOSPHO1, PLA2G12A | BLM 228/4885LMNA 1087/4885PTPN1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.